CPHD up +2.62% percent Today $CPHD High is at 54.7
Post# of 27
Posted On: 11/13/2014 11:43:49 AM
CPHD up +2.62% percent Today $CPHD High is at 54.75 and the Low 53.47 with current volume of 161,843.
Recent News posted below.
Cepheid CPHD other info.
http://investorshangout.com/Cepheid-CPHD-53758/
CPHD Cepheid Recent Headline News
Cepheid receives grant to develop Ebola test
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 7:11AM CST
CPHD: 54.93 (+1.82), CEMI: 4.31 (-0.02)
Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic
PR Newswire - Thu Nov 13, 6:00AM CST
Cepheid (NASDAQ: CPHD) today announced that it has been awarded a grant of up to $3.3 million co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation to develop Xpert® Ebola, a rapid test that could be run on Cepheid's installed base of more than 3,500 GeneXpert® Systems in developing countries, including more than 1,000 in Africa. The test is expected to be offered on an emergency use only basis.
CPHD: 54.93 (+1.82)
Cepheid Shares Up 27.2% Since SmarTrend's Buy Recommendation (CPHD)
Comtex SmarTrend(R) - Tue Nov 11, 9:11AM CST
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 2 months, Cepheid has returned 27.19% as of today's recent price of $52.79.
CPHD: 54.93 (+1.82)
Several Sectors Emerge As Leaders Of New Market Uptrend
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
Every new market uptrend brings new leadership, and this time technology, medical and business service stocks are emerging as market leaders. You can expect sector rotation -- the rise of new leaders as others fall out of favor -- when the market...
VDSI: 27.25 (+0.84), CTAS: 71.41 (+0.10), ABAX: 55.12 (+0.92), CPHD: 54.93 (+1.82), QLYS: 36.21 (+0.22), GK: 65.79 (-0.48), MANH: 40.80 (+0.65), TNET: 31.75 (+0.44), PAYC: 22.92 (+0.57)
Global Polymerase Chain Reaction (PCR) Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, GE Healthcare and Thermo Fisher Scientific
M2 - Thu Nov 06, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/slnt9m/global_polymerase) has announced the addition of the "Global Polymerase Chain Reaction (PCR) Market 2014-2018" report to their offering. Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short period of time. Depending on the requirement, PCR involves different types of reagents, consumables and instruments to process the sample. Advanced software helps to analyze the data generated from the sample processing. The analysts forecast the Global Polymerase Chain Reaction market to grow at a CAGR of 9.19 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Polymerase Chain Reaction market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of products used in PCR. The products considered within the scope of the report are PCR reagents and consumables, instruments, and software and services, which are required to perform PCR. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Affimetrix - Agilent Technologies - BD - Bio-Rad Laboratories - Cepheid - Danaher - Eppendorf - F. Hoffmann-La Roche - Fluidigm - GE Healthcare - Harvard Bioscience - Illumin - PerkinElmer - Promega - Qiagen - RainDanceTechnologies - Sigma-Aldrich - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/sl...polymerase
ABT: 44.65 (+0.42), A: 41.50 (+0.05), CPHD: 54.93 (+1.82), DHR: 82.38 (+0.02), PKI: 43.67 (-0.11)
Cepheid Has Returned 26.3% Since SmarTrend Recommendation (CPHD)
Comtex SmarTrend(R) - Mon Nov 03, 4:38PM CST
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 2 months, Cepheid has returned 26.27% as of today's recent price of $52.41.
CPHD: 54.93 (+1.82)
Cepheid, FIND & Rutgers Announce Collaboration for Next-Generation Innovations to Game-changing Xpert MTB/RIF Test
PR Newswire - Tue Oct 28, 6:00AM CDT
Cepheid (Nasdaq: CPHD), FIND, and Rutgers New Jersey Medical School, today announced details of a collaboration to develop Xpert® MTB/RIF Ultra, a next-generation test for Mycobacterium tuberculosis (TB) with increased sensitivity to aid in detection of patients with smear-negative TB, which is often associated with HIV co-infection. The collaboration is also receiving additional support from the National Institute of Allergy and Infectious Diseases at the NIH1.
CPHD: 54.93 (+1.82)
Stocks Fight Back To Finish Mixed
at Investor's Business Daily - Mon Oct 27, 3:20PM CDT
Stocks clawed back from a weak start to finish mixed Monday. The Nasdaq and Dow each climbed 0.1%, while the S&P 500 dropped 0.2%. Volume was mixed in the stock market today, higher on the NYSE and lower on the Nasdaq, according to preliminary data....
YHOO: 50.31 (-0.29), CMG: 666.58 (+2.33), CPHD: 54.93 (+1.82), SCOR: 43.30 (-0.16)
Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500
at Investor's Business Daily - Mon Oct 27, 2:00PM CDT
Stocks were slightly lower in late trading Monday. But a couple of the major indexes continued to fight near the neutral zone. The Dow Jones industrial average and the Nasdaq were off by 0.1% each. The S&P 500 fell 0.3%, hurt by energy stocks. Energy...
MU: 33.02 (+0.11), GPRO: 78.44 (+1.59), AMGN: 160.60 (-1.33), MPWR: 45.35 (-0.03), CGNX: 41.44 (+0.16), BWLD: 163.67 (+0.67), PANW: 110.59 (+1.70), LCI: 49.87 (+0.14), CPHD: 54.93 (+1.82), TRUE: 16.96 (-0.47), TWTR: 41.92 (-0.62)
Uptrend Call Working As Cepheid Stock Rises 24.0% (CPHD)
Comtex SmarTrend(R) - Mon Oct 27, 10:58AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 2 months, Cepheid has returned 23.99% as of today's recent price of $51.46.
CPHD: 54.93 (+1.82)
Thermo Fisher Tops Earnings, Cuts View on Currency Woes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 1:40PM CDT
Thermo Fisher Scientific's (TMO) adjusted earnings per share (EPS) in the reported quarter came in at $1.71.
ATEC: 1.43 (+0.01), TMO: 118.37 (-0.14), EW: 124.59 (+1.64), CPHD: 54.93 (+1.82)
Intuitive Surgical Q3 Earnings Fall but Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 9:30AM CDT
Intuitive Surgical (ISRG) shipped 111 da Vinci Surgical Systems during the quarter, up from 101 systems in the third quarter of 2013.
ISRG: 522.20 (+8.96), ATEC: 1.43 (+0.01), CPHD: 54.93 (+1.82), ANGO: 16.94 (-0.04)
Genetic Testing Market Outlook 2018 Featuring the Ten Most Active Genetic Testing Market Players Worldwide
M2 - Wed Oct 22, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twtv8n/genetic_testing) has announced the addition of the "Genetic Testing Market Outlook 2018" report to their offering. A recent report, Genetic Testing Market Outlook 2018, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principles and types are covered in this report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 9% during 2013-2018. Our report is an outcome of extensive interaction with industry experts which has led us to portray the updated status of genetic testing in various therapeutic areas, major geographies and significant industry applications. The genetic testing industry has seen several new product launches, active research innovations, strategic activities, launch of new DTC tests, and wider therapeutic applications. The report effectively illustrates the role of genetic testing in diseases such as Cancer, Cystic Fibrosis, and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely, Next-Generation Sequencing, Whole Genome Sequencing, Non Invasive Prenatal Diagnostics, and Personalized Medicine have been covered in the report. Genetic testing is growing in both developing and developed nations with both industry and research personnel highlighting the significance of molecular biology. The report provides comprehensive analytics of key developments for major markets including the U.S., Europe and Asian countries, and their market overview. Country level analysis depicts the level of penetration for genetic testing, types of tests available, consumer perspectives, regulatory stringency and future growth. The report also profiles the ten most active genetic testing market players worldwide: Abbott Laboratories, Roche Diagnostics, Myriad Genetics, Life Technologies, Agilent, Hologic, Illumina, Qiagen, Cepheid, and Affymetrix. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Genetic Testing Overview 4. Global Genetic Testing Market Overview 5. Disease-Wise Analysis 6. Country-Level Analysis 7. Emerging Sectors 8. Genetic Testing Regulation 9. Competitive Assessment - Abbott Laboratories - Affymetrix, Inc. - Agilent Technologies Inc. - Cepheid - Hologic, Inc. - Illumina, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Myriad Genetics, Inc. - Qiagen NV - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/tw...ic_testing
ABT: 44.65 (+0.42), MYGN: 33.40 (+0.41), A: 41.50 (+0.05), CPHD: 54.93 (+1.82), ILMN: 188.31 (+1.39), HOLX: 26.73 (+0.18), AFFX: 9.81 (+0.03)
Cepheid Shares Up 10.5% Since SmarTrend's Buy Recommendation (CPHD)
Comtex SmarTrend(R) - Mon Oct 20, 10:01AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 2 month, Cepheid has returned 10.49% as of today's recent price of $45.86.
CPHD: 54.93 (+1.82)
Cepheid Explores Test For Ebola Disease; Q3 Beats
at Investor's Business Daily - Fri Oct 17, 3:31PM CDT
Molecular diagnostic company Cepheid (CPHD) late Thursday reported a narrower-than-expected Q3 loss and issued Q4 guidance that beat Wall Street views, which sent its shares rising Friday. Cepheid stock was up more than 5% in afternoon trading in the...
CPHD: 54.93 (+1.82)
Update: Cepheid Q3 Earnings - Stock Heading Higher
Andy Batts - at Seeking Alpha - Fri Oct 17, 2:44PM CDT
CPHD: 54.93 (+1.82)
Cepheid Q3 Loss Narrower than Expected, Sales View Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 9:20AM CDT
Cepheid (CPHD) experienced a solid 15.1% year-over-year growth in revenues of $115.2 million in the third quarter.
ATEC: 1.43 (+0.01), CPHD: 54.93 (+1.82), ANGO: 16.94 (-0.04)
Cepheid's (CPHD) CEO John Bishop on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 16, 10:30PM CDT
CPHD: 54.93 (+1.82)
CEPHEID
at Investor's Business Daily - Thu Oct 16, 5:49PM CDT
CEPHEID (CPHD), a molecular analysis equipment maker, lost 1 cent per share in Q3, beating views for a 16-cent loss. Revenue grew 15.1% to $115.2 mil, topping forecasts for $110 mil. Shares rose 4.1% to 46.50.
CPHD: 54.93 (+1.82)
CEPHEID (CPHD) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 16, 3:55PM CDT
CPHD: 54.93 (+1.82)
Recent News posted below.
Cepheid CPHD other info.
http://investorshangout.com/Cepheid-CPHD-53758/
CPHD Cepheid Recent Headline News
Cepheid receives grant to develop Ebola test
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 7:11AM CST
CPHD: 54.93 (+1.82), CEMI: 4.31 (-0.02)
Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic
PR Newswire - Thu Nov 13, 6:00AM CST
Cepheid (NASDAQ: CPHD) today announced that it has been awarded a grant of up to $3.3 million co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation to develop Xpert® Ebola, a rapid test that could be run on Cepheid's installed base of more than 3,500 GeneXpert® Systems in developing countries, including more than 1,000 in Africa. The test is expected to be offered on an emergency use only basis.
CPHD: 54.93 (+1.82)
Cepheid Shares Up 27.2% Since SmarTrend's Buy Recommendation (CPHD)
Comtex SmarTrend(R) - Tue Nov 11, 9:11AM CST
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 2 months, Cepheid has returned 27.19% as of today's recent price of $52.79.
CPHD: 54.93 (+1.82)
Several Sectors Emerge As Leaders Of New Market Uptrend
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
Every new market uptrend brings new leadership, and this time technology, medical and business service stocks are emerging as market leaders. You can expect sector rotation -- the rise of new leaders as others fall out of favor -- when the market...
VDSI: 27.25 (+0.84), CTAS: 71.41 (+0.10), ABAX: 55.12 (+0.92), CPHD: 54.93 (+1.82), QLYS: 36.21 (+0.22), GK: 65.79 (-0.48), MANH: 40.80 (+0.65), TNET: 31.75 (+0.44), PAYC: 22.92 (+0.57)
Global Polymerase Chain Reaction (PCR) Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, GE Healthcare and Thermo Fisher Scientific
M2 - Thu Nov 06, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/slnt9m/global_polymerase) has announced the addition of the "Global Polymerase Chain Reaction (PCR) Market 2014-2018" report to their offering. Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short period of time. Depending on the requirement, PCR involves different types of reagents, consumables and instruments to process the sample. Advanced software helps to analyze the data generated from the sample processing. The analysts forecast the Global Polymerase Chain Reaction market to grow at a CAGR of 9.19 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Polymerase Chain Reaction market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of products used in PCR. The products considered within the scope of the report are PCR reagents and consumables, instruments, and software and services, which are required to perform PCR. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Affimetrix - Agilent Technologies - BD - Bio-Rad Laboratories - Cepheid - Danaher - Eppendorf - F. Hoffmann-La Roche - Fluidigm - GE Healthcare - Harvard Bioscience - Illumin - PerkinElmer - Promega - Qiagen - RainDanceTechnologies - Sigma-Aldrich - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/sl...polymerase
ABT: 44.65 (+0.42), A: 41.50 (+0.05), CPHD: 54.93 (+1.82), DHR: 82.38 (+0.02), PKI: 43.67 (-0.11)
Cepheid Has Returned 26.3% Since SmarTrend Recommendation (CPHD)
Comtex SmarTrend(R) - Mon Nov 03, 4:38PM CST
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 2 months, Cepheid has returned 26.27% as of today's recent price of $52.41.
CPHD: 54.93 (+1.82)
Cepheid, FIND & Rutgers Announce Collaboration for Next-Generation Innovations to Game-changing Xpert MTB/RIF Test
PR Newswire - Tue Oct 28, 6:00AM CDT
Cepheid (Nasdaq: CPHD), FIND, and Rutgers New Jersey Medical School, today announced details of a collaboration to develop Xpert® MTB/RIF Ultra, a next-generation test for Mycobacterium tuberculosis (TB) with increased sensitivity to aid in detection of patients with smear-negative TB, which is often associated with HIV co-infection. The collaboration is also receiving additional support from the National Institute of Allergy and Infectious Diseases at the NIH1.
CPHD: 54.93 (+1.82)
Stocks Fight Back To Finish Mixed
at Investor's Business Daily - Mon Oct 27, 3:20PM CDT
Stocks clawed back from a weak start to finish mixed Monday. The Nasdaq and Dow each climbed 0.1%, while the S&P 500 dropped 0.2%. Volume was mixed in the stock market today, higher on the NYSE and lower on the Nasdaq, according to preliminary data....
YHOO: 50.31 (-0.29), CMG: 666.58 (+2.33), CPHD: 54.93 (+1.82), SCOR: 43.30 (-0.16)
Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500
at Investor's Business Daily - Mon Oct 27, 2:00PM CDT
Stocks were slightly lower in late trading Monday. But a couple of the major indexes continued to fight near the neutral zone. The Dow Jones industrial average and the Nasdaq were off by 0.1% each. The S&P 500 fell 0.3%, hurt by energy stocks. Energy...
MU: 33.02 (+0.11), GPRO: 78.44 (+1.59), AMGN: 160.60 (-1.33), MPWR: 45.35 (-0.03), CGNX: 41.44 (+0.16), BWLD: 163.67 (+0.67), PANW: 110.59 (+1.70), LCI: 49.87 (+0.14), CPHD: 54.93 (+1.82), TRUE: 16.96 (-0.47), TWTR: 41.92 (-0.62)
Uptrend Call Working As Cepheid Stock Rises 24.0% (CPHD)
Comtex SmarTrend(R) - Mon Oct 27, 10:58AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 2 months, Cepheid has returned 23.99% as of today's recent price of $51.46.
CPHD: 54.93 (+1.82)
Thermo Fisher Tops Earnings, Cuts View on Currency Woes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 1:40PM CDT
Thermo Fisher Scientific's (TMO) adjusted earnings per share (EPS) in the reported quarter came in at $1.71.
ATEC: 1.43 (+0.01), TMO: 118.37 (-0.14), EW: 124.59 (+1.64), CPHD: 54.93 (+1.82)
Intuitive Surgical Q3 Earnings Fall but Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 9:30AM CDT
Intuitive Surgical (ISRG) shipped 111 da Vinci Surgical Systems during the quarter, up from 101 systems in the third quarter of 2013.
ISRG: 522.20 (+8.96), ATEC: 1.43 (+0.01), CPHD: 54.93 (+1.82), ANGO: 16.94 (-0.04)
Genetic Testing Market Outlook 2018 Featuring the Ten Most Active Genetic Testing Market Players Worldwide
M2 - Wed Oct 22, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twtv8n/genetic_testing) has announced the addition of the "Genetic Testing Market Outlook 2018" report to their offering. A recent report, Genetic Testing Market Outlook 2018, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principles and types are covered in this report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 9% during 2013-2018. Our report is an outcome of extensive interaction with industry experts which has led us to portray the updated status of genetic testing in various therapeutic areas, major geographies and significant industry applications. The genetic testing industry has seen several new product launches, active research innovations, strategic activities, launch of new DTC tests, and wider therapeutic applications. The report effectively illustrates the role of genetic testing in diseases such as Cancer, Cystic Fibrosis, and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely, Next-Generation Sequencing, Whole Genome Sequencing, Non Invasive Prenatal Diagnostics, and Personalized Medicine have been covered in the report. Genetic testing is growing in both developing and developed nations with both industry and research personnel highlighting the significance of molecular biology. The report provides comprehensive analytics of key developments for major markets including the U.S., Europe and Asian countries, and their market overview. Country level analysis depicts the level of penetration for genetic testing, types of tests available, consumer perspectives, regulatory stringency and future growth. The report also profiles the ten most active genetic testing market players worldwide: Abbott Laboratories, Roche Diagnostics, Myriad Genetics, Life Technologies, Agilent, Hologic, Illumina, Qiagen, Cepheid, and Affymetrix. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Genetic Testing Overview 4. Global Genetic Testing Market Overview 5. Disease-Wise Analysis 6. Country-Level Analysis 7. Emerging Sectors 8. Genetic Testing Regulation 9. Competitive Assessment - Abbott Laboratories - Affymetrix, Inc. - Agilent Technologies Inc. - Cepheid - Hologic, Inc. - Illumina, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Myriad Genetics, Inc. - Qiagen NV - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/tw...ic_testing
ABT: 44.65 (+0.42), MYGN: 33.40 (+0.41), A: 41.50 (+0.05), CPHD: 54.93 (+1.82), ILMN: 188.31 (+1.39), HOLX: 26.73 (+0.18), AFFX: 9.81 (+0.03)
Cepheid Shares Up 10.5% Since SmarTrend's Buy Recommendation (CPHD)
Comtex SmarTrend(R) - Mon Oct 20, 10:01AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 2 month, Cepheid has returned 10.49% as of today's recent price of $45.86.
CPHD: 54.93 (+1.82)
Cepheid Explores Test For Ebola Disease; Q3 Beats
at Investor's Business Daily - Fri Oct 17, 3:31PM CDT
Molecular diagnostic company Cepheid (CPHD) late Thursday reported a narrower-than-expected Q3 loss and issued Q4 guidance that beat Wall Street views, which sent its shares rising Friday. Cepheid stock was up more than 5% in afternoon trading in the...
CPHD: 54.93 (+1.82)
Update: Cepheid Q3 Earnings - Stock Heading Higher
Andy Batts - at Seeking Alpha - Fri Oct 17, 2:44PM CDT
CPHD: 54.93 (+1.82)
Cepheid Q3 Loss Narrower than Expected, Sales View Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 9:20AM CDT
Cepheid (CPHD) experienced a solid 15.1% year-over-year growth in revenues of $115.2 million in the third quarter.
ATEC: 1.43 (+0.01), CPHD: 54.93 (+1.82), ANGO: 16.94 (-0.04)
Cepheid's (CPHD) CEO John Bishop on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 16, 10:30PM CDT
CPHD: 54.93 (+1.82)
CEPHEID
at Investor's Business Daily - Thu Oct 16, 5:49PM CDT
CEPHEID (CPHD), a molecular analysis equipment maker, lost 1 cent per share in Q3, beating views for a 16-cent loss. Revenue grew 15.1% to $115.2 mil, topping forecasts for $110 mil. Shares rose 4.1% to 46.50.
CPHD: 54.93 (+1.82)
CEPHEID (CPHD) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 16, 3:55PM CDT
CPHD: 54.93 (+1.82)
(0)
(0)Cepheid Inc. (CPHD) Stock Research Links
Scroll down for more posts ▼